Rize Oncology Inc. (RZONF)
OTCMKTS · Delayed Price · Currency is USD
0.1600
+0.1596 (39,900.00%)
At close: May 23, 2025
Rize Oncology Company Description
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications.
It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025.
Rize Oncology Inc. was incorporated in 2018 and is based in Kelowna, Canada.
Rize Oncology Inc.
| Country | Canada |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | P. Jull |
Contact Details
Address: 301 – 1665 Ellis Street Kelowna, BC V1Y 2B3 Canada | |
| Phone | 514-796-2640 |
| Website | rizeoncology.com |
Stock Details
| Ticker Symbol | RZONF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| P. Gage Jull B.Sc., C.F.A., M.B.A., P.Eng. | Interim Chief Executive Officer and Director |
| Jim O'Neill | Chief Financial Officer and Corporate Secretary |
| Dr. R. Geoffrey Sargent Ph.D. | Co-Founder and Chief Scientific Officer |